… ProQR Announces First Quarter 2023 Operating and Financial … & CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Announces Results for the Second Quarter of 2017 Key … in need,“ said Daniel de Boer, Chief Executive Officer of ProQR. “We have made significant progress in all of our … to patients in need.” Corporate Highlights In April, ProQR’s QR-110 received clearance of its IND application by …
… ProQR Announces Third Quarter 2022 Operating and Financial … & CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … and Business Operations Updates Axiomer Program In August, ProQR announced the Company will focus exclusively on the …
… ProQR Announces Year End 2024 Operating and Financial Results … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “With up to four clinical trial data readouts …
… ProQR Announces Third Quarter 2023 Operating and Financial … NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We expect that the body of data on our platform and …
… ProQR Announces Second Quarter 2023 Operating and Financial … of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Announces Second Quarter 2025 Operating and Financial … & CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
Advancing AX-0810 through ongoing Phase 1 dosing, with target engagement data expected 1H 2026Selected Development Candidates AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Ended 2025 with € 92.4 million cash and cash equivalents and achie
… ProQR Announces First Quarter 2022 Operating and Financial … & CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … initially liver and CNS, which have strong alignment with ProQR’s oligonucleotide delivery approaches. The Company will …
… ProQR Announces Second Quarter 2024 Operating and Financial … & CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …